Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EMPEROR: Zorevunersen in Dravet Syndrome
NCT06872125Phase 3Active, not recruiting
- Sponsor
- Stoke Therapeutics
- Start
- Jun 2025
- Primary completion
- Mar 2027
- Modality
- Modified DNA Oligonucleotides, Single-strand DNA, Antisense Oligonucleotides (ASOs)
- Countries
- 8
01
Overview
Phase 3, randomised, double-blind trial of zorevunersen in Dravet syndrome (2 arms), sponsored by Stoke Therapeutics. Primary endpoint: Measurement of Seizure Change at 28 weeks. Started Jun 2025; status: active, not recruiting.
02
Drugs
zorevunersen
03
Conditions
Dravet syndrome
Beyond the preview
Go deeper on NCT06872125.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06872125.